BrightGene Bio-Medical Technology Co.,Ltd.

A research-driven biopharmaceutical company, BrightGene engages in the R&D and manufacturing of innovative medicines as well as special generic APIs and finished dosage forms, focused primarily on regulated markets. Its pipeline includes immuno-oncological therapeutic agents, orally available GLP-1 receptor agonist peptides for type 2 diabetes, antibody-drug conjugates for solid tumors, and novel non-antibody tumor-targeting conjugates for brain cancer, alongside a special generic pipeline covering challenging molecules such as eribulin, trabectedin, fondaparinux and caspofungin, non-biological macromolecules like ferumoxytol, and ADC cytotoxic payloads including maytansinoids, auristatins and calicheamicin, supported by cGMP-compliant factories targeting regulated markets.